Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Mark C. Willingham

A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells ⬇️

scientific article published on April 15, 2003

Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage

scientific article published on 23 December 2007

Characterization of single site ricin toxin B chain mutants

scientific article published on January 1996

Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture

scientific article published in October 2003

Diphtheria Toxin−Epidermal Growth Factor Fusion Protein and Pseudomonas Exotoxin−Interleukin 13 Fusion Protein Exert Synergistic Toxicity against Human Glioblastoma Multiforme Cells ⬇️

scientific article published on November 1, 2003

Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. ⬇️

scientific article published on December 2004

Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials

scientific article published on January 2004

GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials

scientific article published on 22 November 2007

Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy

scientific article published in August 2003

IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells

scientific article

Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.

scientific article published on January 2005

PAGE4 is a cytoplasmic protein that is expressed in normal prostate and in prostate cancers.

scientific article published on March 2002

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

scientific article published on 01 September 2007

Paulina is supported by:

About Paulina

Help